Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

The bone mineral density was low and unchanged in all patients.

Who Took Part

The study group was 6 patients.

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

In design terms this was a double-blind, placebo-controlled and crossover study.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

In the crossover set-up each of the patients took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Affect, Bone Density, Cognition, Growth Hormone, Hypopituitarism, Insulin-Like Growth Factor I and Muscle Tonus.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 6 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Acta endocrinologica), a journal based in Denmark.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.